Browsing Tag
Cynata Therapeutics Limited
3 posts
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Cynata Therapeutics advances stem cell trials with strong financial position in March 2025 quarter
Find out how Cynata Therapeutics is driving innovation in regenerative medicine while maintaining a strong financial runway into 2026!
Cynata Therapeutics wraps up patient enrollment for diabetic foot ulcers clinical trial
In a significant development for diabetic foot ulcer treatments, Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology…